Novartis announced results from the Phase II open-label extension ORION-3 trial, which showed that Leqvio provides effective low-density lipoprotein cholesterol (LDL-C) reduction over a four-year period in patients with either atherosclerotic cardiovascular disease (ASCVD) or ASCVD risk equivalent, and elevated LDL-C despite maximally tolerated statin therapy.
- Read more about Leqvio from Novartis shows sustained efficacy and safety
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/leqvio-from-novartis-shows-sustained-efficacy-and-safety
No comments:
Post a Comment